If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
RESPIRATORY
ISSN 2054-3166 October 2014 • emjreviews.com
INSIDE
Review of
ERS 2014
Munich, Germany
CONTENTS
EDITORIAL BOARD................................................................................................................................. 4
CONGRESS REVIEW............................................................................................................................... 8
• Review of the European Respiratory Society Congress, held in Munich, Germany,
6th-10th September 2014
SYMPOSIUM REVIEWS
• There’s more to IgE - Let’s Talk Severe Asthma......................................................................... 28
• COPD Patients’ Needs and Current Treatment Options......................................................... 33
• Nocturnal
RESPIRATORY ISSN 2054-3166
CONTENTS EDITORIAL BOARD......................
RESPIRATORY RATIONALE FOR ENDOBRONCHIAL COIL T
Editorial Board Respiratory Editor-in-Chief: D
Welcome Prevention, education, and innovation are
SUBSCRIBE TO THE EMJ NEWSLETTER www.news.emjre
Foreword Prof Nikolaos Siafakas Department of Tho
ERS ANNUAL CONGRESS 2014 ICM-MESSE MÜNCHEN MUNICH
Welcome to the European Medical Journal review of
ERS ANNUAL CONGRESS 2014 ICM-MESSE MÜNCHEN MUNICH
accepted abstracts, and >100 exhibitors in
ERS ANNUAL CONGRESS 2014 ICM-MESSE MÜNCHEN MUNICH
WHO air quality Guidelines helping to assess
ERS ANNUAL CONGRESS 2014 ICM-MESSE MÜNCHEN MUNICH
DynaPort providing an insight into the life of a
ERS ANNUAL CONGRESS 2014 ICM-MESSE MÜNCHEN MUNICH
Asbestos associated with idiopathic pulmonary fibr
ERS ANNUAL CONGRESS 2014 ICM-MESSE MÜNCHEN MUNICH
New nose technology sniffs out infant asthma type
ERS ANNUAL CONGRESS 2014 ICM-MESSE MÜNCHEN MUNICH
Exhaled breath: new biomarker for lung cancer LU
ERS ANNUAL CONGRESS 2014 ICM-MESSE MÜNCHEN MUNICH
Modern innovations in respiratory care INNOVATION
ERS ANNUAL CONGRESS 2014 ICM-MESSE MÜNCHEN MUNICH
Aerobika coughs 50% of COPD hospital admissions a
ERS ANNUAL CONGRESS 2014 ICM-MESSE MÜNCHEN MUNICH
Click to see BRONCH Express in action Gain Profi
THERE’S MORE TO IgE – LET’S TALK SEVERE ASTHMA Su
Chair’s Opening Comments Professor Roland Buhl Th
immune response. The risk of exacerbations might
Improving the Severe Asthma- Patien
In a discussion around the specific use of
COPD PATIENTS’ NEEDS AND CURRENT
Welcome and Introduction Professor Bartolome Cell
the management of COPD. In terms of p
Glycopyrronium 50 µg q.d. + SFC 50/500 µg b.i.d.
12 and 26 versus the ICS/LABA combination of salm
pneumonia in QVA149-treated patients compared to
Conclusions Professor Bartolome Celli COPD is a
13. Decramer M et al. Indacaterol therapy in pati
NOCTURNAL NON-INVASIVE VENTILATION FOR CHRONIC
several European countries, chronic hypercapn
mortality. Researchers should not focus solely on
352 Assessed for eligibility 157 Excluded
[SGRQ]) in the control group, but there was a sma
0.40 0.30 0.20 Cumulative mortality 0.10
on the respiratory ward, during which ventilation
CPAP favors hypercapnic patients with the overlap
NEW EVIDENCE AND NOVEL THERAPIES FOR
New Clinical Data on the Efficacy and Safety of I
asthma, and comprised data (omalizumab arms, n=85
The APEX study: clinical evidence on exacerbation
New Clinical Evidence on QGE031 (Ligelizumab) ver
therapy was detected, in comparison with th
Overall, QAW039 was associated with a favourable
Congress 2014, Munich, Germany, 6–10 September. 2
NEW OPTIONS FOR OPTIMAL BRONCHODILATION IN C
History of exacerbation Age ICS users
improvement in lung function, dyspnoea, heal
versus placebo or TIO, with significantly improved
New Preclinical Data on Drug Delivery with the Br
revealed a consistent safety profile with regards
COPD exacerbations, with 7.8% of patients sufferi
In another subset,36 the results from 11,858 pati
with QVA149 reduces patient-reported dyspnoea
SUBSCRIBE FREE TO OUR YOUTUBE CHANNEL www.youtube
EVENT-DRIVEN STUDIES AND SERIOUS CHRONIC DI
cohorts who are studied for longer periods, and w
noting that some indirect surrogate endpoint
and therapeutic methods.”17 It is also the
with the methodology used. Importantly, in vitro
REFERENCES 1. Gomberg-Maitland M et al. New tria
RATIONALE FOR ENDOBRONCHIAL COIL TREATMENT A
RATIONALE FOR ENDOSCOPIC TREATMENT OF EMPHYSEMA P
a threshold of >90% integrity to select patients
Figure 1: Sub-segmental coil placement, first
and cost-effectiveness of bilateral coil treatmen
therefore important to carefully consider the ris
patients evaluated with MDCT: incidence and inte
NOVEL INSIGHTS INTO CHRONIC OBSTRUCTIVE PUL
with enhanced breathlessness in COPD, a
source of aberrant CAFs. These activated cells in
membrane proteoglycans (e.g. perlecan), small
are associated with increased airway inflammation,
J Intern Med. 2007;262(3):311-40. 4. Viegi G et a
(COPD) requiring mechanical ventilation. Am J Res
INHALED AMBIENT PARTICULATE MATTER AND
lung cancer, pleural fibrosis, pleural plaques, an
pre-existing COPD. Lee et al.14 have shown that a
systemic circulation, and thereby reach secondary
secondary organ, is highly dependent on the parti
Ambient particulate matter (PM) Hazard/Particle
Oxidative stress and pulmonary inflammation are by
with particulate matter and tobacco smoke exp
INFLUENCE OF AIR POLLUTION ON RESPIRA
Of these common urban air pollutants, PM has been
found to modify the risk of asthma associated wit
significant association between urban background a
alteration of host immunity. Oxidative stres
Respir Crit Care Med. 1999;159(3):768–75. 17. Mud
chemical composition of fine particle air poll
respiratory infections in hospitalized pre-
BRIEF CLINICAL REVIEW: NON-RESPONDING PNEUMONIA
the stages of clinical recovery.12 Microbiol
Although simple, and therefore easier to implemen
use of clinical stability criteria in clinical pr
The second major classification of infectious caus
patients showing any evidence of deteriorati
Standard antibiotic therapy varies gr
Agents Chemother. 2014. [Epub ahead of print]. 20
WHAT’S NEW Bacteria arming newborns against asthm
RESPIRATORY Hsp90 inhibitors used to predict who
WHAT’S NEW App breathes life into fight against pn
RESPIRATORY Anoro®:
WHAT’S NEW Feeling stressed? Just breathe, Spire
RESPIRATORY New drug has potential to combat infla
WHAT’S NEW Belt-busting bellies boost COPD risk
RESPIRATORY Veiled threat of oxygen therapy deman
WHAT’S NEW Lack of knowledge and action underline
From a host of fifteen therapeutic areas, EUROPEAN
Featured Suppliers Respiratory Responsible for
Buyer’s Guide Exhibitors • ACTELION PHARMACEUT
Buyer’s Guide • GERATHERM RESPIRATORY GMBH •
• OXYCARE GMBH • PARI GMBH • PENTAX EUROPE GMBH
UPCOMING EVENTS Contemporary Management of Neona
RESPIRATORY British Thoracic Society (BTS) - Tho
SUBSCRIBE TO RECEIVE THE LATEST CATIONS PUBLI